Compare AbbVie Inc (ABBV) vs Vital Farms Inc (VITL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vital Farms Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Vital Farms Inc trades at $12.35 (market cap $563.24M). The key difference: AbbVie Inc is far larger — about 798.8× Vital Farms Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| ABBV | VITL | |
|---|---|---|
Market Cap | $449.91B | $563.24M |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $52.41 |
52-Week Low | $184.85 | $8.28 |
Enterprise Value | $513.38B | $566.05M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Vital Farms (VITL) trades at $12.84, up 0.63% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported 2025 revenue of $759.44M and net income of $66.28M, though earnings have missed expectations in recent quarters. Analysts maintain a Buy consensus with a $14.00 price target, but negative cash flow and a class action lawsuit pose headwinds.
The stock offers value with a P/E of 12.35 and P/S of 0.75, but risks include declining profitability, legal challenges, and sustained negative cash flow. Upside depends on execution improvements and resolving litigation, while failure to stabilize earnings could pressure valuations further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
